Long-term, low-dose prednisone at less than 5 mg/day appears tolerable and effective for many patients with rheumatoid arthritis (RA)
Search results for: adalimumab
ACR/ARHP Annual Meeting 2012: Risk of Immunosuppression from Rheumatic Disease Therapies Poses Challenge for Rheumatologists
Therapies can raise patients’ risk of contracting tuberculosis or other infectious diseases, complicating treatment
Panel Addresses Drug Safety Issues in Rheumatology Products
Black box warnings, TNF inhibitors, and tofacitinib discussed
ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
People with rheumatic diseases can be considered to receive flu and pneumococcal vaccines even if they’re on immunosuppressive drugs
Rheumatology Drug Updates
Information on new approvals and medication safety rheumatologists need to know
CORRONA Team Provides Data-Based Tool to Address Rheumatology’s Questions
The Consortium of Rheumatology Researchers of North America (CORRONA) patient registry collects a host of treatment and disease indicators for a variety of rheumatic diseases at every physician visit
What Rheumatologists Should Look for in Diagnosing SAPHO Syndrome
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is an obscure condition that can vex patients and clinicians
EULAR 2012: Rewards in Risk Factor Research
Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- Next Page »